OPEN END TURBO PUT WARRANT - ASTRAZENECA ADR | Real-time Boerse Frankfurt Warrants 13:16:35 2024-06-27 EDT | ||
| 0.34 EUR | +51.11% |
|
| Current month | -39.19% | ||
| 1 month | -19.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 0.34 | +51.11% |
| 24-06-26 | 0.225 | +13.64% |
| 24-06-25 | 0.198 | -13.16% |
| 24-06-24 | 0.228 | -18.57% |
| 24-06-21 | 0.28 | -9.68% |
Real-time Boerse Frankfurt Warrants
Last update June 27, 2024 at 01:16 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | UBS |
| WKN | UM5R5B |
| ISIN | DE000UM5R5B0 |
| Date issued | 2024-05-14 |
| Strike | 81.13 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.37 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.54 € |
|---|---|
| Lowest since issue | 0.078 € |
| Spread | 0.01 € |
| Spread % | 2.94% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
158.5
USD
Average target price
174.4
USD
Spread / Average Target
+10.04%
- Stock Market
- Certificates
- Certificat
